• Je něco špatně v tomto záznamu ?

Elevated D-dimer as an immediate response to alemtuzumab treatment

J. Libertinova, E. Meluzinova, E. Nema, P. Rockova, M. Elisak, M. Petrzalka, H. Mojzisova, J. Hammer, A. Tomek, P. Marusic

. 2021 ; 27 (1) : 151-154. [pub] 20200220

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026294

Alemtuzumab as a treatment of highly active multiple sclerosis causes a rapid decrease in inflammatory activity due the lysis of immune cells. Subsequent cytokine release determines the infusion-associated reaction that is a frequent adverse event of alemtuzumab treatment. Recently, serious cardiovascular and thrombotic adverse reactions following alemtuzumab infusion have been described. In our study, the dynamics of coagulation parameters were analyzed in 13 multiple sclerosis patients treated with alemtuzumab. An immediate, significant increase in the level of D-dimer was observed after the first administration of alemtuzumab. This observation provides evidence of coagulation activation and the potential risk of thrombotic complications with this therapy. Prophylactic low molecular weight heparin pretreatment maybe considered in patients receiving alemtuzumab.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026294
003      
CZ-PrNML
005      
20211026133024.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1352458520904277 $2 doi
035    __
$a (PubMed)32077356
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Libertinova, Jana $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
245    10
$a Elevated D-dimer as an immediate response to alemtuzumab treatment / $c J. Libertinova, E. Meluzinova, E. Nema, P. Rockova, M. Elisak, M. Petrzalka, H. Mojzisova, J. Hammer, A. Tomek, P. Marusic
520    9_
$a Alemtuzumab as a treatment of highly active multiple sclerosis causes a rapid decrease in inflammatory activity due the lysis of immune cells. Subsequent cytokine release determines the infusion-associated reaction that is a frequent adverse event of alemtuzumab treatment. Recently, serious cardiovascular and thrombotic adverse reactions following alemtuzumab infusion have been described. In our study, the dynamics of coagulation parameters were analyzed in 13 multiple sclerosis patients treated with alemtuzumab. An immediate, significant increase in the level of D-dimer was observed after the first administration of alemtuzumab. This observation provides evidence of coagulation activation and the potential risk of thrombotic complications with this therapy. Prophylactic low molecular weight heparin pretreatment maybe considered in patients receiving alemtuzumab.
650    _2
$a alemtuzumab $7 D000074323
650    _2
$a fibrin-fibrinogen - produkty degradace $7 D005338
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Meluzinova, Eva $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Nema, Eva $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Rockova, Petra $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Elisak, Martin $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Petrzalka, Marko $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Mojzisova, Hana $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Hammer, Jiri $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Tomek, Ales $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Marusic, Petr $u Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
773    0_
$w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 27, č. 1 (2021), s. 151-154
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32077356 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133030 $b ABA008
999    __
$a ok $b bmc $g 1715114 $s 1146801
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c 1 $d 151-154 $e 20200220 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace